Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Emerging nanotherapeutic strategies in breast cancer.

Blanco E, Ferrari M.

Breast. 2014 Feb;23(1):10-8. doi: 10.1016/j.breast.2013.10.006. Epub 2013 Nov 8. Review.

PMID:
24215984
2.

Nanomedicine in cancer therapy: innovative trends and prospects.

Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M.

Cancer Sci. 2011 Jul;102(7):1247-52. doi: 10.1111/j.1349-7006.2011.01941.x. Epub 2011 May 3. Review.

3.

Nanoparticle technologies for cancer therapy.

Alexis F, Pridgen EM, Langer R, Farokhzad OC.

Handb Exp Pharmacol. 2010;(197):55-86. doi: 10.1007/978-3-642-00477-3_2. Review.

PMID:
20217526
4.

PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.

Shroff K, Kokkoli E.

Langmuir. 2012 Mar 13;28(10):4729-36. doi: 10.1021/la204466g. Epub 2012 Feb 29.

PMID:
22268611
5.

Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.

Malam Y, Loizidou M, Seifalian AM.

Trends Pharmacol Sci. 2009 Nov;30(11):592-9. doi: 10.1016/j.tips.2009.08.004. Review.

PMID:
19837467
6.

Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.

Moura V, Lacerda M, Figueiredo P, Corvo ML, Cruz ME, Soares R, de Lima MC, Simões S, Moreira JN.

Breast Cancer Res Treat. 2012 May;133(1):61-73. doi: 10.1007/s10549-011-1688-7. Epub 2011 Jul 30.

PMID:
21805188
7.

Preclinical and clinical studies of anticancer agent-incorporating polymer micelles.

Matsumura Y, Kataoka K.

Cancer Sci. 2009 Apr;100(4):572-9. Review.

PMID:
19462526
9.

Liposomal chemotherapeutics.

Gentile E, Cilurzo F, Di Marzio L, Carafa M, Ventura CA, Wolfram J, Paolino D, Celia C.

Future Oncol. 2013 Dec;9(12):1849-59. doi: 10.2217/fon.13.146. Review.

PMID:
24295415
10.

Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy.

Prados J, Melguizo C, Ortiz R, Vélez C, Alvarez PJ, Arias JL, Ruíz MA, Gallardo V, Aranega A.

Anticancer Agents Med Chem. 2012 Nov;12(9):1058-70. Review.

PMID:
22339066
11.

Role of integrated cancer nanomedicine in overcoming drug resistance.

Iyer AK, Singh A, Ganta S, Amiji MM.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1784-802. doi: 10.1016/j.addr.2013.07.012. Epub 2013 Jul 21. Review.

PMID:
23880506
12.

Targeted nanoparticulate drug-delivery systems for treatment of solid tumors: a review.

Bhattacharjee H, Balabathula P, Wood GC.

Ther Deliv. 2010 Nov;1(5):713-34. Review.

PMID:
22833959
13.

The use of ultrasound to release chemotherapeutic drugs from micelles and liposomes.

Ahmed SE, Martins AM, Husseini GA.

J Drug Target. 2015 Jan;23(1):16-42. doi: 10.3109/1061186X.2014.954119. Epub 2014 Sep 9. Review.

PMID:
25203857
14.

Future directions of liposome- and immunoliposome-based cancer therapeutics.

Park JW, Benz CC, Martin FJ.

Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205. Review.

PMID:
15717745
15.

The drug discovery by nanomedicine and its clinical experience.

Matsumura Y.

Jpn J Clin Oncol. 2014 Jun;44(6):515-25. doi: 10.1093/jjco/hyu046. Epub 2014 Apr 21. Review.

PMID:
24755547
16.

Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.

Zeng X, Morgenstern R, Nyström AM.

Biomaterials. 2014 Jan;35(4):1227-39. doi: 10.1016/j.biomaterials.2013.10.042. Epub 2013 Nov 7.

17.

Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy.

Yang Y, Pan D, Luo K, Li L, Gu Z.

Biomaterials. 2013 Nov;34(33):8430-43. doi: 10.1016/j.biomaterials.2013.07.037. Epub 2013 Jul 27.

PMID:
23896006
18.

A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment.

Zhang Y, Tang L, Sun L, Bao J, Song C, Huang L, Liu K, Tian Y, Tian G, Li Z, Sun H, Mei L.

Acta Biomater. 2010 Jun;6(6):2045-52. doi: 10.1016/j.actbio.2009.11.035. Epub 2009 Dec 5.

PMID:
19969111
19.

Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.

Prados J, Melguizo C, Rama AR, Ortiz R, Segura A, Boulaiz H, Vélez C, Caba O, Ramos JL, Aránega A.

Cancer Chemother Pharmacol. 2010 May;66(1):69-78. doi: 10.1007/s00280-009-1135-1. Epub 2009 Sep 22.

PMID:
19771430
20.

Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.

Lluch A, Alvarez I, Muñoz M, Seguí MÁ, Tusquets I, García-Estévez L.

Crit Rev Oncol Hematol. 2014 Jan;89(1):62-72. doi: 10.1016/j.critrevonc.2013.08.001. Epub 2013 Aug 21. Review.

PMID:
24071503

Supplemental Content

Support Center